Medical Marijuana Inc (OTCMKTS:MJNA) Is Building A Medical Marijuana Empire South Of The Border

By Chris Sandburg / in Momentum & Growth, Momentum Stocks, Sector Watch, Stocks / on Thursday, 29 Dec 2016 10:10 PM

Medical Marijuana Inc (OTCMKTS:MJNA) continues to climb higher into the close of 2016, as the company continues to push out updates relating to its operations. The company ran up into the November ballot along with the rest of the industry, but dipped into the latter part of the month, as traders took profits off the table. In our last coverage of this one, early December, we concluded that the company had plenty of upside potential left, and that it looked like a nice near to medium term momentum play on the back of this assumption.

We pointed out that the then-recent filing of an IP application by a a company in which Medical Marijuana holds a circa 35% position, Axim Biotechnologies Inc (OTCMKTS:AXIM), moved the latter, but failed to really move the latter, and that this was a bit of a red flag. Not enough to put us off completely, but enough to temper enthusiasm.

Anyway, that was then, this is now. What’s happened over the last few weeks, and what does it mean?

The company has focused on expansion in the central and south American markets, and it’s from this expansion that much of the value-add seen over the last few weeks derives. First up, Medical Marijuana announced that the cannabis regulations had been relaxed in Mexico, and that it was looking to build on its operations in the nation by expanding its full range into the Mexican market. The current product it sells into the space is a product called Real Scientific Hemp Oil-X, and it was the first-ever federally approved CBD product in Mexico. It’s got a portfolio of alternative Real Scientific products waiting in line to get in the country, and now the regulations have eased, the company should be able to start generating multiples of its Mexican revenues near term.

The next major update detailed the expansion of HempMeds (which is the subsidiary that sells the above mentioned product into the Mexican market) into Chile and Argentina. Shortly after that, we got word that the same product had started being sold in Brazil, so that gives HempMeds, and by proxy, Medical Marijuana, a solid presence south of the US border.

For us, these are all great moves, but we’re looking to the US as the market that’s going to drive real value, and as yet, things aren’t moving overly fast. So, that’s what we’re looking for next. Of course, the market is a little less mature in many of the US markets, but in places like California, we feel there is plenty of room for fast expansion. As such, we’re keeping an eye on releases purporting to these above-the-border markets before confirming a long term bias.

With that said, to build a medical marijuana operation in places like Mexico and Brazil is not an easy task, and that Medical Marijuana is making considerable inroads towards this task strengthens a near term these, given its current market capitalization. Weighing the company up against some of its peers in the space, Medical Marijuana has some real positives. It’s generating revenues, it’s got an international distribution network in place, and it’s got a great product in a rapidly growing, yet still very much nascent, industry.

Cash isn’t great, so we expect some degree of dilution if the company is to capitalize on its potential, but so long as management can put together a raise structure that isn’t overtly toxic to shareholders, there’s a definite momentum opportunity on this one.

Look to the continued stream of business development updates from South America to support near term value, and updates relating to the US operations as indicative of longer term potential.

Medical Marijuana Inc (OTCMKTS:MJNA) Is Building A Medical Marijuana Empire South Of The Border

Six Predictions For The Marijuana Industry In 2017

Debra Borchardt ,  

 CONTRIBUTOR

I write about retail and cannabis.  

Opinions expressed by Forbes Contributors are their own.

This year saw big election wins for marijuana in several states. In addition, Colorado crossed the $1 billion mark for annual marijuana sales. Now a new year is almost here and a new presidential administration for the cannabis industry to navigate. It's time to look ahead and see what's in store for the cannabis industry in 2017.

The two biggest areas of focus for the upcoming year are California and Jeff Sessions. With California's recreational marijuana market in the building phase, many in the industry will be watching for progress throughout the year. Another big center of attention will be the appointment of Jeff Sessions as U.S. Attorney General. This will keep the industry on heightened alert for any changes in law enforcement.  Aside from those two topics, here are some of the industry’s biggest predictions for the 2017.

1. Los Angeles Will Become The Marijuana Capital

Move over Denver, Adam Bierman Chief Executive Officer of cannabis investment firm MedMen Capital believes that the City of Angels will steal the spotlight from the Mile High City. Bierman said that by some estimates, Los Angeles's medical marijuana market alone is already close to $1 billion, easily overshadowing Colorado’s entire market. The city is expected to pass an ordinance in 2017 that will clear the path for a proper licensing program and open up the recreational market. Bierman said that capital is flowing into the area for local ventures as investors begin to smell money in the emerging market.

2. A Sports League Will Green Light Marijuana

Bierman believes that in 2017 a major sports league will approve the use of cannabis for medical purposes. Many professional athletes have turned to using cannabis to treat pain and head injuries and are rejecting prescribed opiates. With medical marijuana legal in 29 states, the players are pushing to be treated just like other patients.

3. A Primetime Network Show With A Marijuana Theme

With many polls showing that most Americans approve of legalizing marijuana, it won't be long before a major network will use marijuana as a backdrop. It's been over a decade since Showtime had a hit with Weeds. That series focused on a suburban mom that sold pot to make ends meet. It was considered ground breaking at the time with its taboo topic. Now HBO has High Maintenance and MTV's got Mary + Jane. Adam Scott from Parks and Recreation got a green light from NBC to develop a show called Buds about a dispensary in Denver. There isn't any timeline yet as to when the comedy could hit the air waves.

4. An Increase In Interest For Synthetic CBD

With the Hemp Industries Association and the DEA battling over the legality of cannabis extracts like cannabinoids or CBD, there is an expectation for increased interest in synthetic cannabinoids. Seth Yakatan, the chief executive officer of biotech company Kalytera, said, “With AG Sessions and the DEA's clarification that plant derived CBD isn't legal federally, there will likely be interest in synthetic forms of CBD, which is what Kalytera has been testing the efficacy of for a few years.” Aside from the debate over whether CBD is legal or not, Yakatan is right that synthetic products do not have the legal limitations of other products. However, the synthetic products are not believed to be as effective as the natural products according to some patients. Fear over legal issues could create more demand for the synthetics.

5. The Growth of Craft Marijuana

Sasha Kadey, Chief Marketing Officer of vaporizer distributor Greenlane, said he expects that as market supplies grow, prices will fall, causing a commoditizing effect. “This is leading to premiumization," he said. "Much like the alcohol industry experienced during its maturation, with producers now seeking to differentiate with premium packaging, brand building, so called “seed to sale” storytelling, and other value adds.” Other growers will stress their organic features, while some will push celebrity endorsements. It will be the year of the craft bud.

6. Recycling Marijuana Failures

The Cannabis Business Alliance is hoping to work with lawmakers to create options for marijuana that fails pesticide testing. Currently marijuana producers have to destroy crops that fail testing. The CBA is working towards a new rule to allow for these harvests to be turned into solvent-based concentrates that would be considered safe.

We Are A Company of Firsts

A Company of Firsts - Introduction (Part 1)

Cannabis Science Inc (OTCMKTS:CBIS) Takes A Step Forward

By Steven Goodstein / in Marijuana, Medical / on Tuesday, 13 Dec 2016 12:12 AM

Dr. Wilfred F. Ngwa, the Harvard Director of Global Health Catalyst at the DF/HCC, stated that Cannabis Science Inc (OTCMKTS:CBIS) presentation was a huge success. This development will lead to beneficial partnership opportunities between the firm and Harvard Medical School.
The expert view

Dr. Ngwa said that they were pleasantly surprised with the clearly targeted missions, direct plan of action and knowledge depth offered by Cannabis Science. They discussed the drug development success and advancement the company had made so far. Partnerships between renowned scientists and CBIS team at the DF/HCC are anticipated to bring in-depth knowledge of the potential effectiveness of cannabinoids in the cancer treatment and also other chronic diseases. Dr. Ngwa added that they will outline the motivations for research partnership with a viewpoint of successfully publishing details in a renowned peer-reviewed medical journal.

Mr. Dabney participated in the talks, and together with Melvin F. Foote and Dr. Allen A. Herman, the CMO of Cannabis Science delivered a comprehensive overview of the firm and its “Cannabis Science Research” Foundation. It covered details on cannabinoids treatment, targeting different critical ailments and validating the ability to destroy cancer cells and improve the therapeutic management of different types of cancers. It engaged the Harvard faculty members in deliberating approaches to establishing a research and drug development alliance between Dana Farber/Harvard Cancer Center and Cannabis Science.

Dr. Herman commented that during the roundtable talks, they received an opportunity to discuss prospective pre-clinical, and clinical research plans and objectives with the DF/HCC scientists. The drug advancement targeting will be implemented by the new association and is projected to alter the dynamics of phyto-pharmaceutical progression, particularly in the segments of clinical study design and program implementations.

Raymond C. Dabney, the CEO and President of Cannabis Science, said that with the support of renowned team of scientists of a prestigious cancer research institution, the company hopes to launch new therapies from research to FDA nod much more quickly. The partnership strength is underscored by an in-depth knowledge of the acceptance procedures at the Food and Drug Administration.

Piuttosto che legalizzare la cannabis ... fanno saltare il Governo

Ok. E' caduto il governo. Perchè? Perchè non vogliono legalizzare la cannabis.

Guardiamo i dati. La povertà alla quale questa classe politica ci ha portato, è frutto del loro arricchimento. Che si è fondato, tra le tante balle, che la cannabis non va legalizzata.

Ormai neppure più tutti i berlusconiani sono contro la legalizzazione. E' facile trovare in giornali di destra, titoli a favore della cannabis, sostenuti da idee economiche come quella portata da alcuni premi nobel dell'economia. Esistono ancora dei sostenitori del libero mercato e della libertà individuale. Insomma, non sono tutti fascisti a destra.

Ma torniamo alle dimissioni del premier. Questo governo, che da circa due anni ha incarico la richiesta di autorizzazione alla coltivazione alla cannabis, non si è ancora espresso.

Da un punto di vista economico quanto può avere danneggiato l' Italia?

Ebbene, circa il 20% del pil

Il Sole 24 ore:

Dopo «un quindicennio perduto», il Paese «soffre oggi di una debolezza superiore all’atteso» sottolineano da Viale dell’Astronomia ricordando come il contesto «resta molto difficile» con «tutti gli indicatori qualitativi al ribasso».

Ancora il sole24ore

Confindustria: Italia ferma 15 anni, altri crescono

«Non riusciamo a schiodarci dalla malattia della bassa crescita di cui soffriamo dall’inizio degli anni Duemila» avverte il capo economista di Confindustria, Luca Paolazzi. I dati Csc mostrano come «prima, durante e dopo la Grande Recessione (in Italia più intensa e più lunga) si è accumulato un distacco molto ampio» con altri Paesi Ue. Tra 2000 e 2015, ricorda Confindustria, il Pil è aumentato in Spagna del 23,5%, Francia +18,5%, Germania +18,2%. In Italia è «calato dello 0,5%» e con le dinamiche in corso i gap aumentano oggi «ancor più rapidamente».

Dall'Istat: I NUOVI CONTI NAZIONALI IN SEC 2010  Innovazioni e ricostruzione delle serie storiche (1995-2013),  “Le modifiche connesse al superamento delle riserve europee sull’implementazione del Sec 95 hanno contribuito alla revisione per 0,8 punti percentuali. Di queste, la modifica con il maggior impatto (1,0 punti percentuali) riguarda l’inclusione di alcune attività illegali tra l’economia non osservata.”
Scendendo nel dettagli di questa valutazione economica emergono alcuni dati interessanti elaborati dall’ufficio Statistico.
- “l’inclusione delle importazioni illegali di droga e tabacco di contrabbando ha inciso per 0,2 punti sulla revisione complessiva”
- “La spesa per consumi finali delle famiglie ha subito una revisione al rialzo del 4%, spiegata per 1,6 punti percentuali dalle riserve (quasi interamente connessa all’inclusione dell’economia illegale”

Avete mai sentito Renzi parlare di "riserve da parte dell'europa?"Di 13 miliardi di flessibilità?Indovinate un pò di che flessibilità parla quando fa riferimento a quei numeri?Al mercato della cannabis!

Sempre nella nota informativa: "La componente più rilevante tra le tre attività illegali ora misurate dai conti nazionali riguarda la commercializzazione di droga, la quale, in termini di valore aggiunto, è valutata nel 2011 in 10,5 miliardi di euro.
....
Il valore aggiunto derivante da attività illegali è il risultato di una produzione valutabile in circa 16 miliardi a fronte della quale si stima un ammontare di costi intermedi pari a 1,7 miliardi; questi ultimi generano, a loro volta, un valore aggiunto di 1,2 miliardi connesso alla produzione di beni e servizi legali indotta da attività illegali (Prospetto 4). Pertanto, la stima delle attività illegali, comprensiva dell’indotto, comporta un’integrazione di valore aggiunto nei conti pari a 15,5 miliardi di euro, con un’incidenza sul nuovo livello del Pil pari, nel 2011 allo 0,9%. "

(Prospetto 4)

Se si confrontano i dati di confindustria, con le stime pil dell'Istat con le conseguenze delle scelte politiche sul tema cannabis, emerge un dato "drogato". Eh si. I dati italiani non sono attendibili. La politica italiana ha nascosto all'Europa, un business ,da 13 miliardi di euro l'anno, che avrebbe potuto portare l'italia a crescere al passo di Spagna, Germania e battere con orgoglio i cugini francesi.

L' uno per cento del pil che il mercato della cannabis ha sottratto ai dati ufficiali è allarmante e andrebbe messo in regola. Come? legalizzando la cannabis e dichiarando il mercato aperto e libero all'impresa.

Questa è una battaglia per lo sviluppo economico e la lotta alla povertà.

Istat, un residente su quattro in Italia è a rischio povertà o esclusione sociale: al Sud quasi il 50%

L' incidenza di 1,7 punti percentuali annui, per 15 anni, avrebbe reso l'italia più ricca, semplicemente facendo una somma aritmetica, di 25.5 punti percentuali di incidenza. Divenendo la locomotirice d'europa.

Ma la cannabis non è mai stata legale. E dunque oggi siamo poveri e (in)felici.

Ma queste argomentazioni potrebbero essere troppo tecniche. Perciò l' economia, per rendersi più accessibile, ha spiegato il pil come il reddito dello stato e, semplificando, la crescita del pil come la crescita del reddito del cittadino. Significa che 25.5 punti di pil persi, è il 25% perso nella crescita del  reddito medio di un cittadino italiano. L' italiano è in media più povero. ora si può dire per causa della repressione di un mercato illegale.

L' Italia con la cannabis legale? Lo stato più potente d'europa.

Cannabis capitalists: the business leaders hoping for a marijuana boom

The 2016 Election And The Marijuana Vote | MSNBC

Marijuana Sector Remains One of Markets Hottest Industry Behind Newest Products and Services

PALM BEACH, Florida, November 16, 2016 /PRNewswire/ --

The exploding cannabis and legal marijuana industry, globally and within the United States, is calling for a significant expansion and improvement of both services and operations as marijuana stocks within the industry aim to capitalize on the unprecedented momentum. Active companies in the sector this week include: Vemanti Group, Inc. (OTC: VMNT), Medical Marijuana, Inc. (OTC: MJNA), Agritek Holdings, Inc. (OTC: AGTK), Cannabix Technologies Inc. (OTC: BLOZF) and Medical Cannabis Payment Solutions (OTC: REFG).

Vemanti Group, Inc. (OTC PINK: VMNT) a diversified holding corporation, announced today that its preparing to launch a new wholly-owned subsidiary, which will look to provide a comprehensive mobile commerce and payments service for the emerging cannabis industry. Through their smartphones, the service will enable retail customers to pay for goods at any participating dispensary without using physical cash. It will also present dispensaries, growers, and other legitimate participants of the industry with the opportunity of carrying out non-retail transactions among themselves in digital payments. 

Read the full Vemanti (VMNT) Press Release at: http://marketnewsupdates.com/news/vmnt.html

The Company believes that the emerging legal cannabis industry where retail and non-retail transactions, including vendor payments and payroll, are almost exclusively paid for with cash presents a real challenge for financial institutions. Concerned about the evolving conflict between federal and state laws, they are eager to avoid the inherent risks associated with this cash-intensive sector. It is widely acknowledged that many are unwilling to go to the expense of establishing and maintaining the type of thorough due diligence program for this emerging market at the present time in order to comply with growing demands of Know-Your-Customer (KYC) guidelines, anti-money laundering regulations, and the US Patriot Act. As the result, traditional banking and payment solutions have been out of reach for the vast majority of cannabis businesses.

"The cannabis industry needs access to digital payments in order to grow, and consumers want a safe and secure way to purchase marijuana products without always relying on cash. Our goal for the new subsidiary is to launch a service that alleviates the risk of cash transactions and helps dispensaries monitor and record data needed to address concerns about violating anti-money laundering laws, with the long-term goal of moving transactions away from cash altogether. It will comply with every relevant regulatory requirement and provide a sustainable solution for the cannabis industry", commented Tan Tran, CEO of Vemanti Group.

In other cannabis developments and happenings to watch this week in the markets:

StoneBridge Partners, LLC -- a global finance communication and consulting firm -- announces the release of an in-depth business analysis of Medical Marijuana, Inc. (OTC PINK: MJNA) presented in a comprehensive report. The report, which outlines the company's formation and current operations, also offers insight into the perceived opportunities in the explosive-growth market of cannabis. It explores the Company's diversified portfolio of cannabis organizations and brands that continue to flourish as new markets open and existing markets continue to develop

Agritek Holdings, Inc. (OTC: AGTK) closed down slightly on Tuesday on just over 6.88 Million shares traded by the market close. Agritek Holdings, Inc. offers various products and services to the medicinal marijuana sector in the United States. It distributes hemp-based nutritional products; and provides solutions for electronically processing merchant transactions.

Cannabix Technologies Inc. (OTC Pink: BLOZF) closed up over 24% on Tuesday at $0.59 on just under 1 Million shares traded by the market close. Cannabix Technologies, developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, recently released images of its Beta 2.0 Cannabix Marijuana Breathalyzer. New images of the device can be viewed at http://www.cannabixtechnologies.com.

Medical Cannabis Payment Solutions (OTC: Pink: REFG) works to solve the fragmentation problem by identifying tools that are important to dispensaries, and customizing those tools specifically catered to the industry. We strive to create awareness within the medicinal marijuana industry and to develop an environmentally friendly, economically sustainable business while increasing shareholder value.

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Vemanti Group, Inc.. by the company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:
Media Contact email: info@marketnewsupdates.com - +1-(561)325-8757

SOURCE MarketNewsUpdates.com
Marijuana Sector Remains One of Markets Hottest Industry Behind Newest Products and Services

U.S. Patent Allowance Granted to Medical Marijuana, Inc.'s Investment AXIM(R) Biotech for Use of All Cannabinoids in Its Controlled Release Chewing Gum

SAN DIEGO, CA--(Marketwired - November 16, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA) announced today that its major investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601, a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from the application, filed in April 2015. This patent covers the inclusion of all cannabinoids (both natural and synthetic) in a chewing gum delivery system, including Tetrahydrocannabinol (THC), all of which may be incorporated in the Company's chewing gum products.

This new patent is an extension of AXIM® Biotech's patent for chewing gum as delivery methods for cannabidiol (Chewing Gum Compositions Comprising Cannabinoids). Prior to this new allowance, Patent 9,023,322 only claimed gum products as a delivery mechanism for cannabidiol (CBD), a well-known cannabinoid.

"We congratulate the AXIM team on receiving this new patent, another major milestone in the Company's continued efforts to research new solutions using cannabinoid-based drugs," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.

"This patent will enable AXIM to include any of the at least 85 different cannabinoid compounds found in the cannabis plant, including CBD and THC, into its multiple cannabinoid controlled-release chewing gum products," added Dr. Titus. "As investors in AXIM, we are enthusiastic about how the Company continues to move forward as a leader in cannabinoid research and development."

AXIM® Biotech developed the patents it now owns for chewing gum as a delivery method for cannabinoids into two separate products. Its CBD-only Canchew® gum is marketed and is legal to purchase wherever CBD hemp oil products are sold. AXIM® Biotech holds the exclusive rights to market and distribute CanChew® Gum globally. CanChew® is a botanical hemp-derived CBD chewing gum with a unique oral mucosal absorbance delivery system. Features listed on the CanChew® website include:

• Non-habit forming
• No prescription needed
• Available in all 50 states
• Great-tasting mint gum has no artificial sweeteners or preservatives
• Non-GMO, gluten free, vegan and kosher

In addition, AXIM® will start clinical trials for its combination CBD/THC gum, MedChew® Rx, for the treatment of pain and spasticity associated with multiple sclerosis. Directly compared to a sublingually delivered cannabis-based product currently on the market for MS, the estimated market size for MedChew® Rx is $4.8 billion USD. MedChew® Rx is on track to be fully registered by the EMA and FDA.

AXIM has also developed CanChew Plus™ CBD containing gum with improved delivery system and doses of 10 mg of CBD and 30mg of CBD which is set to begin clinical trials in the EU. Besides these, AXIM has developed CanChew Rx™, which is based on pharmaceutical-grade, 99.9% pure CBD crystals, extracted and manufactured based on company IPs and containing 10, 30, 50, 100 and 150 mg of CBD in microencapsulated form (AXIM IP) for significantly increased bioavailability of the Active Pharmaceutical Ingredient.

Another AXIM® Biotech patent-pending cannabis innovation in clinical trials is AX-1602. The first of its kind, AX-1602 contains CBG (cannabigerol) and other cannabinoids as a treatment for psoriasis and atopic dermatitis.

AXIM® Biotech's core belief is responsibility for environmental stewardship combined with development of innovative products to address conditions with no currently known effective treatment including: Parkinson's disease, Alzheimer's disease/dementia, ADHD(attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

U.S. Patent Allowance Granted to Medical Marijuana, Inc.'s Investment AXIM(R) Biotech for Use of All Cannabinoids in Its Controlled Release Chewing Gum